Further structure-activity relationship studies on 4-((((3 S,6 S)-6-benzhydryltetrahydro-2 H -pyran-3-yl)amino)methyl)phenol: Identification of compounds with triple uptake inhibitory activity as potential antidepressant agents

Journal of Medicinal Chemistry

Volumn 54, Issue 8, 2011, Pages 2924-2932

  Gopishetty, Bhaskar ^a   Hazeldine, Stuart ^a   Santra, Soumava ^a   Johnson, Mark ^a   Modi, Gyan ^a   Ali, Solav ^b   Zhen, Juan ^b   Reith, Maarten ^b   Dutta, Aloke ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[(6 BENZHYDRYLTETRAHYDRO 2H PYRAN 3 YL)AMINO]METHYL]PHENOL; 4 [[(6 BENZHYDRYLTETRAHYDRO 2H PYRAN 3 YL)AMINO]METHYL]PHENOL; 6 BENZHYDRYL N (4 METHOXYBENZYL)TETRAHYDRO 2H PYRAN 3 AMINE; 6 BENZHYDRYL N (THIOPHEN 2 YLMETHYL)TETRAHYDRO 2H PYRAN 3 AMINE; ANTIDEPRESSANT AGENT; AROMATIC COMPOUND; DOPAMINE TRANSPORTER; FLUOXETINE; HETEROCYCLIC COMPOUND; IMIPRAMINE; N [(1H PYRROL 2 YL)METHYL] 6 BENZHYDRYLTETRAHYDRO 2H PYRAN 3 AMINE; NORADRENALIN TRANSPORTER; PHENYL GROUP; PYRROLE DERIVATIVE; REBOXETINE; SEROTONIN TRANSPORTER; THIOPHENE DERIVATIVE; TRIPLE REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CHEMICAL REACTION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; DRUG UPTAKE; FORCED SWIMMING TEST; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; MAGNETIC RESONANCE SPECTROSCOPY; NEUROTRANSMITTER UPTAKE INHIBITORS; PYRANS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79955462284     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200020a     Document Type: Article

References (32)

1. Kessler, R. C.; Berglund, P.; Demler, O.; Jin, R.; Koretz, D.; Merikangas, K. R.; Rush, A. J.; Walters, E. E.; Wang, P. S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA, J. Am. Med. Assoc. 2003, 289, 3095-3105 (Pubitemid 37432885)
2. Lopez, A. D.; Murray, C. C. The global burden of disease, 1990-2020 Nat. Med. 1998, 4, 1241-1243 (Pubitemid 28512100)
3. Dilsaver, S. C.; Chen, Y. W.; Swann, A. C.; Shoaib, A. M.; Krajewski, K. J. Suicidality in patients with pure and depressive mania Am. J. Psychiatry 1994, 151, 1312-1315 (Pubitemid 24281755)
4. Strakowski, S. M.; McElroy, S. L.; Keck, P. E., Jr.; West, S. A. Suicidality among patients with mixed and manic bipolar disorder Am. J. Psychiatry 1996, 153, 674-676 (Pubitemid 26133620)
5. Nemeroff, C. B. Psychopharmacology of affective disorders in the 21st century Biol. Psychiatry 1998, 44, 517-525 (Pubitemid 28496678)
6. Iversen, L. Neurotransmitter transporters: fruitful targets for CNS drug discovery Mol. Psychiatry 2000, 5, 357-362 (Pubitemid 30455948)
7. Schloss, P.; Williams, D. C. The serotonin transporter: a primary target for antidepressant drugs J. Psychopharmacol. 1998, 12, 115-121 (Pubitemid 28312567)
8. Nierenberg, A. A.; Amsterdam, J. D. Treatment-resistant depression: definition and treatment approaches J. Clin. Psychiatry 1990, 51 (Suppl.) 39-47; discussion 48-50 (Pubitemid 20212863)
9. Nierenberg, A. A.; Quitkin, F. M.; Kremer, C.; Keller, M. B.; Thase, M. E. Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse Neuropsychopharmacology 2004, 29, 1012-1018 (Pubitemid 38526801)
10. D'Aquila, P. S.; Collu, M.; Gessa, G. L.; Serra, G. The role of dopamine in the mechanism of action of antidepressant drugs Eur. J. Pharmacol. 2000, 405, 365-373
11. Papakostas, G. I. Dopaminergic-based pharmacotherapies for depression Eur. Neuropsychopharmacol. 2006, 16, 391-402 (Pubitemid 43975351)
12. Clayton, A. H.; Warnock, J. K.; Kornstein, S. G.; Pinkerton, R.; Sheldon-Keller, A.; McGarvey, E. L. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction J. Clin. Psychiatry 2004, 65, 62-67
13. Damsa, C.; Bumb, A.; Bianchi-Demicheli, F.; Vidailhet, P.; Sterck, R.; Andreoli, A.; Beyenburg, S. "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review J. Clin. Psychiatry 2004, 65, 1064-1068
14. Skolnick, P.; Popik, P.; Janowsky, A.; Beer, B.; Lippa, A. S. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor Eur. J. Pharmacol. 2003, 461, 99-104 (Pubitemid 36174028)
15. Shaw, A. M.; Boules, M.; Zhang, Y.; Williams, K.; Robinson, J.; Carlier, P. R.; Richelson, E. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050 Eur. J. Pharmacol. 2007, 555, 30-36 (Pubitemid 46013855)
16. Skolnick, P.; Basile, A. S. Triple reuptake inhibitors ("broad spectrum" antidepressants) CNS Neurol. Disord.: Drug Targets 2007, 6, 141-149 (Pubitemid 46681774)
17. Liang, Y.; Shaw, A. M.; Boules, M.; Briody, S.; Robinson, J.; Oliveros, A.; Blazar, E.; Williams, K.; Zhang, Y.; Carlier, P. R.; Richelson, E. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1 S,2 S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS) J. Pharmacol. Exp. Ther. 2008, 327, 573-583
18. Skolnick, P.; Krieter, P.; Tizzano, J.; Basile, A.; Popik, P.; Czobor, P.; Lippa, A. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor CNS Drug Rev. 2006, 12, 123-134 (Pubitemid 44300380)
19. Dutta, A. K.; Davis, M. C.; Reith, M. E. Rational design and synthesis of novel 2,5-disubstituted cis- and trans-piperidine derivatives exhibiting differential activity for the dopamine transporter Bioorg. Med. Chem. Lett. 2001, 11, 2337-2340 (Pubitemid 32781694)
20. Dutta, A. K.; Davis, M. C.; Fei, X. S.; Beardsley, P. M.; Cook, C. D.; Reith, M. E. Expansion of structure-activity studies of piperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine (GBR 12935) compounds by altering substitutions in the N -benzyl moiety and behavioral pharmacology of selected molecules J. Med. Chem. 2002, 45, 654-662 (Pubitemid 34145711)
21. Ghorai, S. K.; Cook, C.; Davis, M.; Venkataraman, S. K.; George, C.; Beardsley, P. M.; Reith, M. E.; Dutta, A. K. High affinity hydroxypiperidine analogues of 4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidine for the dopamine transporter: stereospecific interactions in vitro and in vivo J. Med. Chem. 2003, 46, 1220-1228 (Pubitemid 36428227)
22. Dutta, A. K.; Zhang, S.; Kolhatkar, R.; Reith, M. E. Dopamine transporter as target for drug development of cocaine dependence medications Eur. J. Pharmacol. 2003, 479, 93-106 (Pubitemid 37377879)
23. Zhang, S.; Reith, M. E.; Dutta, A. K. Design, synthesis, and activity of novel cis- and trans-3,6-disubstituted pyran biomimetics of 3,6-disubstituted piperidine as potential ligands for the dopamine transporter Bioorg. Med. Chem. Lett. 2003, 13, 1591-1595 (Pubitemid 36428567)
24. Kolhatkar, R.; Cook, C. D.; Ghorai, S. K.; Deschamps, J.; Beardsley, P. M.; Reith, M. E.; Dutta, A. K. Further structurally constrained analogues of cis -(6-benzhydrylpiperidin-3-yl)benzylamine with elucidation of bioactive conformation: discovery of 1,4-diazabicyclo[3.3.1]nonane derivatives and evaluation of their biological properties for the monoamine transporters J. Med. Chem. 2004, 47, 5101-5113 (Pubitemid 39314908)
25. Zhang, S.; Zhen, J.; Reith, M. E.; Dutta, A. K. Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis -(6-benzhydryl- piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters Bioorg. Med. Chem. 2004, 12, 6301-6315 (Pubitemid 39440465)
26. Zhang, S.; Zhen, J.; Reith, M. E.; Dutta, A. K. Discovery of novel trisubstituted asymmetric derivatives of (2 S,4 R,5 R)-2-benzhydryl-5- benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner J. Med. Chem. 2005, 48, 4962-4971 (Pubitemid 41038458)
27. Zhang, S.; Fernandez, F.; Hazeldine, S.; Deschamps, J.; Zhen, J.; Reith, M. E.; Dutta, A. K. Further structural exploration of trisubstituted asymmetric pyran derivatives (2 S,4 R,5 R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3 S,6 S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters J. Med. Chem. 2006, 49, 4239-4247 (Pubitemid 44036667)
28. Dutta, A. K.; Ghosh, B.; Biswas, S.; Reith, M. E. D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action Eur. J. Pharmacol. 2008, 589, 73-79
29. Lewis, D. B.; Matecka, D.; Zhang, Y.; Hsin, L. W.; Dersch, C. M.; Stafford, D.; Glowa, J. R.; Rothman, R. B.; Rice, K. C. Oxygenated analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3- phenylpropyl)piperazines (GBR 12935 and GBR 12909) as potential extended-action cocaine-abuse therapeutic agents J. Med. Chem. 1999, 42, 5029-5042
30. Porsolt, R. D.; Le Pichon, M.; Jalfre, M. Depression: a new animal model sensitive to antidepressant treatments Nature 1977, 266, 730-732 (Pubitemid 8073804)
31. Cryan, J. F.; Markou, A.; Lucki, I. Assessing antidepressant activity in rodents: recent developments and future needs Trends Pharmacol. Sci. 2002, 23, 238-245 (Pubitemid 34465544)
32. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108